Theravance Biopharma, Inc. - Ordinary Shares (TBPH) Social Stream
Theravance Biopharma Inc (TBPH) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering TBPH.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 33 weeks, TBPH's average price target has gone down $19.44.
TBPH reports an average of 74.01% for its upside potential over the past 41 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
TBPH Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
TBPH's average broker recommendation rating worsened by 1.01 over the prior 15 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of all US stocks, Theravance Biopharma Inc's variance in analysts' estimates is lower than -178.5% of them.
- In terms of how Theravance Biopharma Inc fares relative to all US stocks, note that its average analyst price target is higher than 37.81% of that group.
- TBPH has a greater upside potential (average analyst target price relative to current price) than 53.35% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Theravance Biopharma Inc's number of analysts covering the stock is greater than 186.25% of them.
What is the outlook for TBPH? Use POWR Ratings for clearer insight into price direction.